Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Partial Epilepsies Clear all
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Tolerability of BHV-7000

NCT06443463
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
115
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Not listed Phase 1 Interventional

Exercise for Brain Regeneration in Epilepsy

NCT05179083
View directory record Official record
Conditions
Temporal Lobe Epilepsy
Interventions
High-Impact Aerobic Exercise, Low-Impact Aerobic Exercise
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

NCT02844465
View directory record Official record
Conditions
Temporal Lobe Epilepsy
Interventions
Visualase MRI-Guided Laser Ablation
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
23
States / cities
Newport Beach, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

NCT00152451
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (ucb 44212)
Drug
Lead sponsor
UCB S.A. - Pharma Sector
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
7
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699
View directory record Official record
Conditions
Major Depression, Temporal Lobe Epilepsy
Interventions
escitalopram, placebo
Drug
Lead sponsor
Conrad, Erich J., M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01190098
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Lacosamide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

NCT00150800
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB PHARMA Inc. (US)
Industry
Eligibility
16 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery

NCT04986683
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Brain magnetic resonance imaging, Neuro-psychology testing
Diagnostic Test · Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
3 Years to 19 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

NCT05081518
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Investigations of Amygdala Function Using Neurophysiological Recording and Stimulation

NCT03958903
View directory record Official record
Conditions
Fear, PTSD, Panic Disorder
Interventions
Amygdala recording and stimulation using Neuropace RNS, Behavioral tasks
Device · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.

NCT00426673
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (ucb34714)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

NCT00141388
View directory record Official record
Conditions
Seizure Disorder, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2009 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

NCT01501383
View directory record Official record
Conditions
Epilepsy
Interventions
VX-765 Part A, Placebo, VX-765 Part B
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
22
States / cities
Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

NCT01964560
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Long-term Cardiac Monitoring in Epilepsy

NCT03955432
View directory record Official record
Conditions
Focal Epilepsy, Intractable Epilepsy, Epileptic Encephalopathy, Lennox Gastaut Syndrome, Symptomatic Epilepsy, Generalized Epilepsy
Interventions
Reveal LINQ ICM System
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

NCT06422923
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
NRTX-1001
Biological
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

NCT01318408
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
60 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Localizing Epileptic Networks Using MRI and iEEG

NCT04649008
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
Interventions
3T Magnetic Resonance Imaging, Intracranial electroencephalography recordings, 7T Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00144690
View directory record Official record
Conditions
Epilepsy
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Tampa, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

NCT00151879
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

NCT00056576
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Zonisamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
16 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

NCT00310375
View directory record Official record
Conditions
Epilepsy
Interventions
Ezogabine: USAN Retigabine (International Nonproprietary Name)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 17, 2026, 4:08 AM EDT